Our Challenge

Due to a number of factors, research has not made significant progress in improving outcomes or identifying new therapies in metastatic osteosarcoma patients in over 30 years…

The OSI intends to help change that.

Our Ambition

The Osteosarcoma Institute will develop and execute a comprehensive, rational strategy to improve the life expectancy of relapsed and metastatic patients by 10x.

Our Strategy

  • Capitalize on recent advances in science to overcome resource & knowledge gaps that have hindered progress
  • Develop convincing justifications for biotechnology and pharmaceutical companies to produce new therapeutics
  • Engage patients and their friends, families, & advocates
  • Commit to provide significant seed funding & raise the additional funding required to achieve the goal

Director

Lee Helman, MD

institute executive board

Mac Tichenor, chair

Bret Alexander

Mary Katherine Clarke

Richard Gorlick, MD

Lee Helman, MD

Chand Khanna, DVM, PhD, ex officio

Sung Poblete, RN, PhD

Bill Tap, MD

Dan Von Hoff, MD

Scientific advisory board

Chand Khanna, DVM, PhD, chair

Jim Amatruda, MD, PhD

Michael Brown, MD

Lee Helman, MD

Katherine Janeway, MD

Cigall Kadoch, PhD

Bob Mennel, MD

Melinda Merchant, MD, PhD

Bob Schreiber, PhD

Stay Informed

Join our mailing list to stay informed

Help us concentrate on the cure and let us know how you and your organization can participate.

We respect your time and privacy.  We will only email when we have something important to say about our plans or our work, and will not share the contact information you provide here with any third parties.

Get Involved

We are currently accepting applications for our
Patient Advocacy Program.

Click below to fill out an application today!